Harmony Biosciences Holdings, Inc. (HRMY)
ValueMarkers Composite Index
78% below intrinsic value ($128)
Harmony Biosciences Holdings, Inc. (HRMY) — VMCI valuation read
HRMY screens at VMCI 69/100, a 19-point gap above the Healthcare sector median (50). For a mid-cap Harmony Biosciences Holdings, Inc. share, that placement says the multi-pillar composite is cheaper or higher quality than the typical peer on a like-for-like basis.
HRMY has logged no Form 4 insider activity over the trailing 30 days. The tape reads neither bullish nor bearish on insider conviction. The next signal sits with the 10-Q schedule and the analyst calendar.
**Investor frame.** Value: HRMY trades at 24.0x earnings, 33% above the Healthcare median of 18.0x, while EV/EBITDA prints 9.0x against 12.0x for the Healthcare group. Quality: ROIC of 12.0% sits 2.0pp above the Healthcare median (10.0%), the cleanest like-for-like comparison on capital efficiency. Risk: net debt to EBITDA of 1.1x leaves covenant headroom, which sets the rate-cycle exposure for Harmony Biosciences Holdings, Inc..
HRMY rose 3.5% over the trailing 7 days, with a -6.0% read on a 30-day basis.
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvania.
Related Stocks in Healthcare
Top peers ranked by VM Score. Compare valuation, quality, and risk metrics across the sector.